Comparative Pharmacology
Head-to-head clinical analysis: CERADON versus FLOVENT DISKUS 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CERADON versus FLOVENT DISKUS 50.
CERADON vs FLOVENT DISKUS 50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Unknown; possibly enhances cognitive function by modulating cholinergic and dopaminergic pathways.
Glucocorticoid receptor agonist; anti-inflammatory transcription factor modulation; inhibits phospholipase A2, reduces arachidonic acid release, decreases prostaglandin and leukotriene synthesis; suppresses cytokine production and inflammatory cell migration.
500 mg orally every 8 hours; for severe infections, 750 mg every 12 hours or 1 g every 8 hours.
1 inhalation (50 mcg) twice daily, administered via oral inhalation.
None Documented
None Documented
3-5 hours in healthy adults; prolonged to 8-12 hours in moderate renal impairment (CrCl 30-50 mL/min) and up to 20 hours in severe impairment (CrCl <30 mL/min).
Terminal elimination half-life is approximately 14-17.5 hours; this supports once- or twice-daily dosing in asthma maintenance.
Renal: 60-70% unchanged; biliary/fecal: 20-30% as metabolites; total: >90% eliminated within 48 hours.
Primarily fecal (87-90%) after hepatic metabolism; renal excretion accounts for <5% as unchanged drug and metabolites.
Category C
Category C
Corticosteroid
Corticosteroid